Immunovant Inc Stock

Market capitalization is the stock price multiplied by the number of shares issued.

Immunovant Inc

Enterprise value (EV) is a measure of the value of a company regardless of its financing. It is calculated as follows:
EV = market capitalization - cash + debt.

Enterprise Value metric explained

Immunovant Inc

The P/E ratio or price/earnings ratio TTM (Trailing Twelve Months) over the last 12 months describes the ratio of the stock price to earnings per share.

Immunovant Inc

If you divide the enterprise value by the Free Cash Flow of the last 12 months, you obtain an important metric for assessing the valuation of companies - even if they are not yet generating profits.

Immunovant Inc

The P/B ratio TTM (Trailing Twelve Months) over the last 12 months describes the ratio of the stock price to the book value per share.

Immunovant Inc

Revenue TTM (Trailing Twelve Months) represents the sum of all revenues of a company for its products, services or other items within the last 12 months.

Immunovant Inc

EBIT or the operating result represents the profit or loss after deducting direct costs (cost of sales), sales, marketing, administrative, research and development costs and depreciation and amortization.

Immunovant Inc

Free Cash Flow TTM (Trailing Twelve Months) provides information on how much of the profit generated over the last 12 months remains in the company's coffers and is therefore available for profit distributions, share buybacks or debt repayment.

Immunovant Inc

Cash is defined as cash and cash equivalents (i.e. cash items of very high value).

Immunovant Inc

EPS TTM (Trailing Twelve Months) or earnings per share represents the profit per share over the last 12 months. The company's net profit is divided by the number of shares.

Immunovant Inc

Price/earnings ratio based on the expected net earnings per share for the financial year ending at Mar 31 2026.

Immunovant Inc

Ratio of market capitalization to sales on the basis of expected sales for the financial year ending at Mar 31 2026

Immunovant Inc

Ratio of enterprise value to sales based on estimated sales for the financial year ending at Mar 31 2026

Immunovant Inc